Cefixime

From Self-sufficiency
Jump to: navigation, search
Cefixime
File:Cefixime.svg
Systematic (IUPAC) name
(6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Pregnancy
category
  • B
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 40% to 50%
Protein binding Approximately 60%
Biological half-life Variable
Average 3 to 4 hours
Excretion Renal and biliary
Identifiers
CAS Number 79350-37-1
ATC code J01DD08 (WHO)
PubChem CID 5362065
DrugBank APRD00583
ChemSpider 4514923
Chemical data
Formula C16H15N5O7S2
Molar mass 453.452 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Cefixime is an oral third generation cephalosporin antibiotic. It is used to treat gonorrhea,[1] tonsilitis,[2] and pharyngitis.[2]

The usual dose is 400 mg in two divided doses for up to 5-7 days.

It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA.


References

  1. McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime". Int J STD AIDS. 18 (4): 253–4. doi:10.1258/095646207780658971. PMID 17509176. 
  2. 2.0 2.1 Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy". Infection. 23 (Suppl 2): S83–6. doi:10.1007/BF01742990. PMID 8537138. 
ar:سيفيكزيم

fr:Céfixime it:Cefixima pl:Cefiksym pt:Cefixima th:เซฟิกซิม